MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma
Miller, Michael B.
Ramkissoon, Lori A.
Kang, Yun Jee
Knoff, David S.
Ramkissoon, Shakti H.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationMiller, M. B., W. L. Bi, L. A. Ramkissoon, Y. J. Kang, M. Abedalthagafi, D. S. Knoff, P. K. Agarwalla, et al. 2016. “MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma.” Oncotarget 7 (24): 37054-37063. doi:10.18632/oncotarget.9244. http://dx.doi.org/10.18632/oncotarget.9244.
AbstractPituitary spindle cell oncocytoma (SCO) is an uncommon primary pituitary neoplasm that presents with mass effect on adjacent neurovascular structures, similar to non-hormone-producing pituitary adenomas. To determine the molecular etiology of SCO, we performed exome sequencing on four SCO cases, with matched normal controls, to assess somatic mutations and copy number alterations. Our analysis revealed a low mutation rate and a copy-neutral profile, consistent with the low-grade nature of this tumor. However, we identified a co-occurring somatic HRAS (p.Q61R) activating point mutation and MEN1 frameshift mutation (p.L117fs) present in a primary and recurrent tumor from one patient. Other SCOs demonstrated mutations in SND1 and FAT1, which are associated with MAPK pathway activation. Immunohistochemistry across the SCO cohort demonstrated robust MAPK activity in all cases (n=4), as evidenced by strong phospho-ERK staining, while phospho-AKT levels suggested only basal levels of PI3K pathway activation. Taken together, this identifies the MAPK signaling pathway as a novel therapeutic target for spindle cell oncocytoma, which may offer a powerful adjunct for aggressive tumors refractory to surgical resection.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29626074
- HMS Scholarly Articles